Stockholders' Equity (Details Narrative) - USD ($)			1 Months Ended									12 Months Ended
	Sep. 12, 2019	Jan. 07, 2019	Feb. 29, 2020	Feb. 24, 2020	Feb. 14, 2020	Jan. 31, 2020	Nov. 24, 2019	Aug. 31, 2019	Aug. 16, 2019	May 31, 2019	Feb. 28, 2019	Jul. 31, 2020	Jul. 31, 2019	Mar. 10, 2020	Mar. 09, 2020	Nov. 25, 2019	Dec. 01, 2018	Nov. 30, 2018	Jul. 31, 2018
Authorized share capital														760,000,000	400,000,000
Common stock, par value (in dollars per share)												$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized												750,000,000	750,000,000	750,000,000
Common stock, shares issued												82,251,801	78,608,419
Common stock, shares outstanding												82,251,801	78,608,419
Preferred stock, par value (in dollars per share)														$ 0.001
Preferred stock, shares authorized														10,000,000
Stock split				1.4:1 stock split
Common stock issued for conversion debt, Shares												11,914,545	2,297,812
Common stock issued for conversion debt, Value											$ 350,000	$ 5,348,847	$ 18,406,684
Shares issued for services, value												334,400
Shares to be issued												$ 10,079,449	$ 1,123,188						$ 2,168,951
NGIO
Common stock, shares issued												400,300,000
Common stock, shares outstanding												400,300,000
Oasis Capital, LLC
Shares issued, shares																40,000,000
Joe Moscato TTEE
Cancellation of shares	20,375,900
B-H Sanford, LLC
Common stock issued upon conversion of preferred stock																	28,828,953
Moscato
Common stock issued upon conversion of preferred stock																		7,595,350
Vendors
Stock issued for conversion of note payable, Shares													1,733,924
Stock issued for conversion of note payable, Value													$ 870,554
Shares issued for services, shares			789,803			789,803						32,610	6,762,000
Shares issued for services, value			$ 334,400			$ 334,400						$ 14,500	$ 1,097,100
Shares reserved for future issuance, shares													30,000
Shares reserved for future issuance, value													$ 69,000
Creditor
Stock issued for conversion of note payable, Shares												373,510
Stock issued for conversion of note payable, Value												$ 852,895
Shares reserved for future issuance, shares												3,499,415	341,790
Shares reserved for future issuance, value												$ 1,472,826	$ 852,891
Veneto Downside Protection
Shares reserved for future issuance, shares												16,470,588
Shares reserved for future issuance, value												$ 8,400,000
Creditor 1
Shares reserved for future issuance, shares												30,000
Shares reserved for future issuance, value												$ 14,500
MediSource
Common stock issued for acquisition								400,000
Pantheon
Common stock issued for acquisition								560,000
Olaregen
Equity method investment, shares									900,000
Ownership percentage									77.00%
Shareholders
Shares issued, shares					5,950,000
Investors
Common stock issued for conversion debt, Shares												343,000
Common stock issued for conversion debt, Value												$ 151,230
Former Stockholders
Common stock issued for conversion debt, Value					$ 32,212
Non-controlling interest shareholders
Common stock, shares issued												36,296,849
Common stock, shares outstanding												36,296,849
Olaregen
LOI Terms		Pursuant to the Company’s acquisition of Olaregen on January 7, 2019 to acquire a 51% interest, the Company was issued 3,282,632 shares of Olaregen common stock from Olaregen shareholders. In May 2019, the Company issued 4,000,000 shares of common stock contributed and provided by the Friends of Generex Trust and a $2 million note payable for the acquisition of 592,683 shares of Series A Preferred Stock of Olaregen pursuant to a Stock Purchase Agreement entered into January 14, 2019 subject to the approval of the Board of Directors of Olaregen and consummated on May 10, 2019
Regentys
LOI Terms		Pursuant to the Company’s acquisition of Regentys on January 7, 2019 to acquire a 51% interest, the Company was issued 12,048,161 shares of Regentys common stock. As of July 31, 2020, Regentys had a total of 18,623,278 shares of common stock and 2,793,192 Series A voting preferred stock for a total of 21,416,470 total voting shares outstanding. As such, there are 9,368,309 of shares that belong to non-controlling interest shareholders which represents a 43.74% non-controlling interest.
Stock Purchase Agreement | Olaregen
Common stock issued for acquisition							4,250,000			4,000,000
Notes payable for acquisition										$ 2,000,000
Number of Preferred Stock										592,683
Oasis Capital Agreement
Shares issued, shares																1,719,901